Navigation Links
Mylan Announces Appointment of Jagdish Dore' as CEO and Managing Director of Matrix Laboratories
Date:2/27/2008

PITTSBURGH, Feb. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Jagdish Viswanath Dore' as CEO and Managing Director of Matrix Laboratories Limited. Mr. Dore' will assume the responsibilities of Rajiv Malik who became Executive Vice President and Head of Global Technical Operations for Mylan in October 2007 and has been serving as interim CEO for Matrix, a majority-owned subsidiary of Mylan. Mr. Malik will relocate to the United States in connection with his employment by Mylan.

Mr. Dore' joins Matrix after a distinguished 29 year career with Sandoz most recently as Managing Director and India Country Head. In this role, Mr. Dore' was responsible for all of Sandoz's operations in India including global development and manufacturing; local and export sales; day-to-day operations; and technical operations in the Asia Pacific region. He was previously responsible for business operations in the Asia Pacific cluster and involved in the startup of Novartis Enterprises Private Limited (now Sandoz), Novartis Consumer Health India Private Limited and Master Builders Technology India Private Limited, India.

Matrix Chairman and Mylan Vice Chairman and CEO Robert J. Coury said: "Jagdish's impressive industry reputation is well known, and I believe he will be a huge asset to Matrix as it continues to expand its integral role in support of Mylan's global platform. I have every confidence that Jagdish will ensure that Matrix continues its strong growth and supports Mylan in becoming the world's leading, fully-integrated generic pharmaceuticals company."

N. Prasad, Matrix's Vice Chairman, commented, "I have known Jagdish for some time, and I am absolutely delighted that he will be assuming Rajiv's role as CEO of Matrix. During his tenure at Sandoz, Jagdish was responsible for managing the company's 1,800 employees based in India along with developing a rapidly growing business across the Asia Pacific region. He brings a great deal of experience on a strategic and operational level that will be invaluable to Matrix as it strengthens its leadership in active pharmaceutical ingredients (API), further develops its finished dosage form (FDF) capabilities and continues to grow its antiretroviral (ARV) business."

Mr. Dore' said: "Matrix is an established, highly respected and high- quality company in the pharmaceuticals industry both in India and world-wide. It is only enhanced by being part of Mylan. I look forward to leading Matrix into the next phase of its growth and working with the Mylan and Matrix senior management teams to further align our organizations and leverage the opportunities available to us in the global generics market."

Mr. Dore' earned a Bachelor of Technology degree from the Indian Institute of Technology, Chennai, and a postgraduate degree in business management from the Xavier Institute in Jamshedpur specializing in marketing.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
2. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
3. Mylan Restores Availability of Generic Levothyroxine in Florida
4. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
5. Mylan Declares Quarterly Preferred Stock Dividend
6. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
7. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
8. Mylan Sets Date of 2008 Annual Meeting
9. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
10. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
11. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... The Society ... MSW, has decided to move on from that role. , “No one in Washington ... did Phyllis Greenberger,” said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... to residents of Westchester County for over 24 years, recently hosted its sixth ... members joined HOW for two remembrance ceremonies, each concluding with the release of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... information management systems (LIMS), electronic laboratory notebook systems (ELNS) and related systems is ... manual data management consumes a significant amount of lab technician time and introduces ...
(Date:5/23/2016)... ... May 23, 2016 , ... SPH ... as Chief Medical Officer. Dr. O’Connor’s deep expertise in medicine and HIT will ... services teams who deliver best-in-class solutions and transformative technologies for provider, payer, and ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... ABU DHABI , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International ... under the distinguished patronage and presence of Sheikh ... Development. The conference focused in Precision Medicine, which helps provide ...
(Date:5/23/2016)... FRANCISCO , May 23, 2016 ... to reach USD 5.0 billion by 2022, according to ... increasing generation of medical waste coupled with the lack ... industry is expected to drive the demand for reprocessed ... these devices as compared to that of the original ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology: